BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Inflammatory gene profiling of Ewing sarcoma family of tumors (set B)

Dataset: Inflammatory gene profiling of Ewing sarcoma family of tumors (set B)

Purpose: Unlike in most adult-onset cancers, an association between typical paediatric neoplasms and inflammatory triggers is rare. We...

Registered by ArrayExpress Uploader
View Dataset

Purpose: Unlike in most adult-onset cancers, an association between typical paediatric neoplasms and inflammatory triggers is rare. We studied whether immune system related genes are activated and have prognostic significance in Ewing sarcoma family of tumours (ESFT). Experimental design: Data-analysis was performed on gene expression profiles of 44 ESFT patient, 11 ESFT cell line, and 18 normal muscle tissue samples. 238 inflammation related genes were selected based on literature and a macrophage gene expression signature was derived from SymAtlas. Differential expression of the genes was analysed by t-test and survival analysis was performed according to gene expression. Results: Inflammatory genes are activated in ESFT patient samples, as 38 of 238 (16%) inflammatory genes were significantly upregulated (p<0.001) when compared to ESFT cell lines. This inflammatory gene activation was characterized by significant enrichment of macrophage related gene expression with 58 of 299 (19%) of these genes being upregulated (p<0.001). By combining expression data from ESFT patients, cell lines and muscle tissue samples we were able to identify a total of 32 presumptive inflammatory genes that characterize and distinguish tumour site in vivo from surrounding normal tissues. High expression of C5 correlated with better event free (p=0.01) and overall survival (p=0.004) in dose dependent manner. C5 and its receptor C5aR1 expression was verified at protein level by immunohistochemistry on tumor tissue microarray. Also, high expression of JAK1 correlated with favourable overall survival (p=0.04) and high expression of IL8, derived presumably from infiltrating immune cells, resulted in poor overall survival in Ewing sarcoma (p=0.04). Conclusions: Immune system related gene activation is observed in ESFT patient samples and several prognostically significant inflammatory genes (C5, JAK1 and IL8) for ESFT were identified. 44 Ewing sarcoma family of tumor patient and 18 normal muscle samples obtained from GSE6798 and GSE3526.

Species:
human

Samples:
62

Source:
E-GEOD-17674

Updated:
Dec.12, 2014

Registered:
Sep.15, 2014


Factors: (via ArrayExpress)
Sample STATUS SAMPLE ID EFS (MONTHS) OVS (MONTHS) AGE SEX STATE TISSUE DIAGNOSIS
GSM440999 dead R194 11.7 15.6 32 F Primary tumor Ewing
GSM441000 dead R196 14 20.7 5 M Primary tumor Ewing
GSM44100 dead R29 4.6 4.6 21 M Primary tumor Ewing
GSM441002 NED R30 28.6 48.9 26 F Primary tumor Ewing
GSM441003 dead R33 16.6 16.6 15 M Primary tumor Ewing
GSM441004 AWD R34 19.4 56.5 18 M Primary tumor Ewing
GSM441005 dead R35 10 13.6 16 F Primary tumor Ewing
GSM441006 dead R37 9.8 9.8 11 M Primary tumor Ewing
GSM441007 dead R38 11.3 11.3 23 M Primary tumor Ewing
GSM441008 dead R39 47 47 16 F Primary tumor Ewing
GSM441009 NED R40 18.2 117.3 24 M Primary tumor Ewing
GSM441010 NED R41 125.1 125.1 15 M Primary tumor Ewing
GSM4410 NED R42 192.2 192.2 18 M Primary tumor Ewing
GSM441012 dead R43 24.8 35.7 17 F Recurrence tumor Ewing
GSM441013 dead R44 19.8 25.6 30 F Recurrence tumor Ewing
GSM441014 dead R45 17.9 24.6 15 M Recurrence not specified Askin
GSM441015 dead R46 22.1 64.2 7 F Primary not specified PNET
GSM441016 dead R48 31.6 46.2 17 M Metastasis tumor Ewing
GSM441017 NED R49 18.6 126.2 34 M Metastasis tumor Ewing
GSM441018 dead R50 58.3 99.3 16 M Metastasis not specified PNET
GSM441019 dead R51 4.6 10.9 24 M Primary not specified Askin
GSM441020 dead R52 14.4 23.2 22 F Recurrence tumor Ewing
GSM44102 NED R53 87.7 87.7 19 F Primary tumor Ewing
GSM441022 dead R54 25.9 61.5 22 M Recurrence tumor Ewing
GSM441023 dead R55 6.8 8.5 16 F Metastasis not specified PNET
GSM441024 dead R57 2 8.7 11 M Primary tumor Ewing
GSM441025 dead R58 13.4 13.4 22 M Primary tumor Ewing
GSM441026 NED R60 121.5 121.5 12 M Primary tumor Ewing
GSM441027 NED R61 16.2 16.2 15 M Primary tumor Ewing
GSM441028 NED R62 117.6 117.6 16 M Primary tumor Ewing
GSM441029 NED R63 43.4 43.4 13 M Primary tumor Ewing
GSM441030 dead R64 15.3 21.3 25 M Primary tumor Ewing
GSM44103 dead R65 11 11 20 F Primary tumor Ewing
GSM441032 dead R67 16.7 29.4 14 M Primary tumor Ewing
GSM441033 NED R69 62.6 62.6 9 F Primary tumor Ewing
GSM441034 NED R72 31.5 117.7 32 F Primary not specified PNET
GSM441035 NED R74 110.4 110.4 27 M Primary not specified PNET
GSM441036 dead R75 9.8 25.4 14 M Primary not specified PNET
GSM441037 NED R78 69.5 69.5 11 F Primary not specified PNET
GSM441038 NED R79 127.1 127.1 21 M Primary not specified PNET
GSM441039 NED R80 23.9 68.5 8 F Primary not specified PNET
GSM441040 dead R81 34.4 81.4 24 M Metastasis tumor Ewing
GSM44104 NED R83 70.1 129.1 4 F Metastasis not specified PNET
GSM441042 dead R84 27.9 41.6 9 M Metastasis tumor Ewing
GSM441044 not specified not specified not specified not specified not specified not specified not specified skeletal muscle normal
GSM441044 not specified not specified not specified not specified not specified not specified not specified skeletal muscle normal
GSM441044 not specified not specified not specified not specified not specified not specified not specified skeletal muscle normal
GSM441044 not specified not specified not specified not specified not specified not specified not specified skeletal muscle normal
GSM441044 not specified not specified not specified not specified not specified not specified not specified skeletal muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal
GSM441049 not specified not specified not specified not specified not specified not specified not specified vastus lateralis muscle normal

Tags

  • cell
  • ewing sarcoma
  • immune system
  • line
  • macrophage
  • muscle
  • protein
  • sarcoma

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2022 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use